IceCure Medical - ICCM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.50
  • Forecasted Upside: 171.32%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.29
▼ -0.04 (-3.01%)

This chart shows the closing price for ICCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IceCure Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICCM

Analyst Price Target is $3.50
▲ +171.32% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for IceCure Medical in the last 3 months. The average price target is $3.50, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 171.32% upside from the last price of $1.29.

This chart shows the closing price for ICCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in IceCure Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$3.00Low
9/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$3.00Low
8/15/2023Alliance Global PartnersLower TargetBuy ➝ Buy$4.25 ➝ $4.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$3.00Low
7/25/2023HC WainwrightReiterated RatingBuy ➝ Buy$3.00Low
3/28/2023HC WainwrightReiterated RatingBuy$3.00Low
3/20/2023HC WainwrightReiterated RatingBuyLow
10/25/2022Maxim GroupInitiated CoverageBuy$3.00Low
5/19/2022Alliance Global PartnersLower TargetBuy ➝ Buy$9.50 ➝ $5.75Low
2/2/2022Brookline Capital AcquisitionInitiated CoverageBuy$5.65Low
2/1/2022Brookline Capital ManagementReiterated RatingBuyLow
1/14/2022Alliance Global PartnersLower Target$14.50 ➝ $9.50Low
9/22/2021Alliance Global PartnersInitiated CoverageBuy$14.50Medium
(Data available from 2/22/2019 forward)

News Sentiment Rating

-0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/26/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
8/25/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/24/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
11/23/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
12/23/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
1/22/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
2/21/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
IceCure Medical logo
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Read More

Today's Range

Now: $1.29
Low: $1.28
High: $1.32

50 Day Range

MA: $1.25
Low: $0.92
High: $1.48

52 Week Range

Now: $1.29
Low: $0.52
High: $1.57

Volume

76,223 shs

Average Volume

699,149 shs

Market Capitalization

$58.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of IceCure Medical?

The following Wall Street sell-side analysts have issued reports on IceCure Medical in the last twelve months: Alliance Global Partners, and HC Wainwright.
View the latest analyst ratings for ICCM.

What is the current price target for IceCure Medical?

2 Wall Street analysts have set twelve-month price targets for IceCure Medical in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 171.3%. Alliance Global Partners has the highest price target set, predicting ICCM will reach $4.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for IceCure Medical in the next year.
View the latest price targets for ICCM.

What is the current consensus analyst rating for IceCure Medical?

IceCure Medical currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ICCM will outperform the market and that investors should add to their positions of IceCure Medical.
View the latest ratings for ICCM.

What other companies compete with IceCure Medical?

Other companies that are similar to IceCure Medical include Pro-Dex, GBS, Lucid Diagnostics, Carmell and SEP Acquisition. Learn More about companies similar to IceCure Medical.

How do I contact IceCure Medical's investor relations team?

The company's listed phone number is 972-4623-0333 and its investor relations email address is [email protected]. The official website for IceCure Medical is www.icecure-medical.com. Learn More about contacing IceCure Medical investor relations.